accountthe data aren't yet known, some doctors and investors suspect the ' Arbiter 6' trial will show that Abbott Laboratories' (ABT) Niaspan cholesterol drug was superior to Merck's and Schering's Zetia at slowing the thickening of the arteries. The study is...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Merck/Schering Cholesterol Drugs At Another Crossroads
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
